Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

NCT04920032 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Colon Adenocarcinoma
Colorectal Cancer

Interventions

DRUG: TAS-102
DRUG: Irinotecan
COMBINATION_PRODUCT: Standard Treatment
DIAGNOSTIC_TEST: Signatera MRD ctDNA Assay

Sponsor

University of California, Irvine

Collaborators

[object Object]
[object Object]